Investors focused on the Medical space have likely heard of Humana (HUM), but is the stock performing well in comparison to the rest of its sector peers? One simple way to answer this question is to take a look at the year-to-date performance of HUM and the rest of the Medical group's stocks.
Humana is a member of our Medical group, which includes 841 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. HUM is currently sporting a Zacks Rank of #2 (Buy).
Over the past three months, the Zacks Consensus Estimate for HUM's full-year earnings has moved 1.79% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.
Based on the latest available data, HUM has gained about 23.38% so far this year. Meanwhile, stocks in the Medical group have gained about 1.62% on average. This means that Humana is outperforming the sector as a whole this year.
Looking more specifically, HUM belongs to the Medical - HMOs industry, which includes 12 individual stocks and currently sits at #89 in the Zacks Industry Rank. Stocks in this group have gained about 22.27% so far this year, so HUM is performing better this group in terms of year-to-date returns.
HUM will likely be looking to continue its solid performance, so investors interested in Medical stocks should continue to pay close attention to the company.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Humana Inc. (HUM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
